Regulatory FDA clears first genetic hearing loss gene therapy PharmaphorumRegeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.RegulatoryGene TherapyRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) Pharmaphorum Regeneron’s Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US. RegulatoryGene TherapyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cumberland to sell drug portfolio to Apotex for $100mNext: Cumberland to sell drug portfolio to Apotex for $100m Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
